Status:
TERMINATED
Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
Lead Sponsor:
Duke University
Conditions:
Fatty Liver
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to find out if Metformin is safe and useful in the treatment of NAFLD.
Detailed Description
NAFLD is a poorly understood disease which may cause an enlarged liver, abnormal liver test results, and scarring of the liver. It may occur more often in people with obesity, high levels of cholester...
Eligibility Criteria
Inclusion
- biopsy-proven NAFLD, determined within 12 months of study initiation
Exclusion
- \> 20 grams of alcohol/day
- impaired oral glucose tolerance test
- known diagnosis of diabetes mellitus
- hepatitis C infection
- cirrhosis
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00736385
Start Date
April 1 2009
End Date
December 1 2012
Last Update
January 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710